Global Cord Blood Corp Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of CNY, except per-share amounts

	Q4 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Apr 1, 2019	Q4 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Mar 31, 2015	Q4 FY2014 As of Mar 31, 2014	Q4 FY2013 As of Mar 31, 2013	Q4 FY2012 As of Mar 31, 2012
ASSETS
Current assets
Cash and cash equivalents
Trading securities
Accounts receivable, less allowance for credit losses (March 31, 2021: RMB137,961; March 31, 2022: RMB160,445 (US$25,309))
Inventories
Prepaid expenses and other receivables
Current debt issuance costs
Deferred tax assets
Amounts due from related parties
Total current assets

Property, plant and equipment, net
Non-current prepayments
Operating lease right-of-use assets
Non-current deposits
Non-current accounts receivable, less allowance for credit losses (March 31, 2021: RMB67,095; March 31, 2022: RMB59,037 (US$9,313))
Inventories
Intangible assets, net
Available-for-sale equity securities
Other investment
Non-current debt issuance costs
Investment in equity securities at fair value
Other equity investment
Deferred tax assets
Total assets

LIABILITIES
Current liabilities
Bank loan
Convertible notes, net
Accounts payable
Accrued expenses and other payables
Amount due to a related party
Operating lease liabilities
Deferred revenue
Income tax payable
Deferred tax liabilities
Total current liabilities

Convertible notes, net
Non-current deferred revenue
Non-current operating lease liabilities
Other non-current liabilities
Deferred tax liabilities
Total liabilities

EQUITY
Shareholders' equity of Global Cord Blood Corporation
Ordinary shares - US$0.0001 par value, 250,000,000 shares authorized, 121,687,974 shares issued and 121,551,075 shares outstanding as of March 31, 2021 and 2022, respectively
Additional paid-in capital
Treasury stock, at cost (March 31, 2015 and 2016: 136,899 shares, respectively)
Treasury stock, at cost (March 31, 2021 and 2022: 136,899 shares, respectively)
Accumulated other comprehensive losses
Retained earnings
Total equity attributable to Global Cord Blood Corporation

Non-controlling interests
Total equity
Total liabilities and equity

Comments